<DOC>
	<DOC>NCT00479076</DOC>
	<brief_summary>The primary objective of this study is to determine the recommended phase II dose of AVE0005 in combination with S-1 in Japanese cancer patients. The secondary objectives of this study are to assess the safety profile of AVE0005, to determine the pharmacokinetics of AVE0005, to make a preliminary assessment of antitumor effects.</brief_summary>
	<brief_title>A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients</brief_title>
	<detailed_description />
	<criteria>Histologically confirmed cancer patients without standard of care ECOG performance status 0, 1, or 2 Adequate organ and bone marrow function Need for a major surgery or radiation therapy during the study History of hypersensitivity to S1 Known dihydropyrimidine dehydrogenase deficiency Uncontrolled hypertension History of brain metastases Ascites requiring drainage Pregnancy or breastfeeding Patients who have previously been treated with AVE0005 The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>antineoplastic agents</keyword>
	<keyword>VEGF Trap</keyword>
</DOC>